ADIL insider filings
ADIAL PHARMACEUTICALS, INC. — 38 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-21. Screen ADIL transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 2 filings by 1 insider — 14,986 shares, $41,329 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
- Largest priced transaction: purchase of 10,053 shares @ $2.79 ($28,048) by Coastlands Capital LP, filed 2026-07-13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Coastlands Capital LP — 10% owner | 2 | 4 legs · 14,986 sh · $41,329 | — | — |
| Young Wendy B. — Director | 1 | — | — | 1 |
Recent insider filings — ADIAL PHARMACEUTICALS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-21 | 4 | Young Wendy B. — Director | Grant/award (A): 25,666 (derivative) @ $0 | EDGAR |
| 2026-07-16 | 4 | Coastlands Capital LP — 10% owner | Purchase (P): 2,000 @ $2.65 · Purchase (P): 1,233 @ $2.75 | EDGAR |
| 2026-07-13 | 4 | Coastlands Capital LP — 10% owner | Purchase (P): 10,053 @ $2.79 · Purchase (P): 1,700 @ $2.70 | EDGAR |
| 2026-07-01 | 4 | Coastlands Capital LP — 10% owner | Purchase (P): 25,000 @ $2.60 | EDGAR |
| 2026-06-16 | 4 | Davidson Matt — Chief Development Officer, Director | Grant/award (A): 61,647 · Grant/award (A): 3,427 · Grant/award (A): 232,417 @ $0 · Grant/award (A): 1,822.13 · Grant/award (A): 101.30 · Grant/award (A): 232,417 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Young Wendy B. — Director | Purchase (P): 36,378 (derivative) @ $2.75 | EDGAR |
| 2026-04-09 | 4 | Anderson J. Kermit — Director | Grant/award (A): 9,185 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | Goodman Tony — Chief Operating Officer, Director | Grant/award (A): 26,510 @ $0 | EDGAR |
| 2026-04-09 | 4 | Shah Vinay — Chief Financial Officer | Grant/award (A): 17,325 @ $0 | EDGAR |
| 2026-04-09 | 4 | Schuyler Kevin — Director | Grant/award (A): 9,185 @ $0 | EDGAR |
| 2026-04-09 | 4 | Gilliland Robertson H. — Director | Grant/award (A): 9,185 @ $0 | EDGAR |
| 2026-04-09 | 4 | Claiborne Cary J — Chief Executive Officer, Director | Grant/award (A): 37,985 @ $0 | EDGAR |
| 2025-06-02 | 4 | Gilliland Robertson H. — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Newman James W. Jr. — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Shah Vinay — Chief Financial Officer | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Schuyler Kevin — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Goodman Tony — Chief Operating Officer, Director | Grant/award (A): 94,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Anderson J. Kermit — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Claiborne Cary J — Chief Executive Officer, Director | Grant/award (A): 138,000 (derivative) @ $0 | EDGAR |
| 2024-12-05 | 4 | Claiborne Cary J — Chief Executive Officer, Director | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2024-11-18 | 4 | Shah Vinay — Chief Financial Officer | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Gilliland Robertson H. — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Newman James W. Jr. — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Truluck Joseph — Chief Financial Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Anderson J. Kermit — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Schuyler Kevin — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Goodman Tony — Chief Operating Officer, Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Claiborne Cary J — Chief Executive Officer, Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2023-10-03 | 4 | Schuyler Kevin — Director | Purchase (P): 700 @ $2.74 | EDGAR |
| 2023-06-02 | 4 | Johnson Bankole A. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Truluck Joseph — Chief Financial Officer | Grant/award (A): 157,500 @ $0 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Stilley William B. III — Director | Grant/award (A): 240,800 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Schuyler Kevin — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Newman James W. Jr. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Goodman Tony — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Gilliland Robertson H. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Anderson J. Kermit — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Claiborne Cary J — Chief Executive Officer, Director | Grant/award (A): 420,000 @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — ADIAL PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-25 | 8-K | 3.02 — Unregistered Sales of Equity Securities | EDGAR |
| 2026-08-21 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2026-08-11 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ADIL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →